Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom
October 14 2021 - 7:45AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its wholly owned
subsidiary, Pasithea Clinics, has partnered with ZEN Healthcare to
offer intravenous (“IV”) ketamine therapy to patients suffering
from treatment-resistant mental health issues. Initially, the
treatment will be offered in Knightsbridge, London, beginning
October 2021.
Pasithea Therapeutics recently raised $24
million at its initial public offering (“IPO”). The Company’s
Common Stock began trading on The Nasdaq Capital Market on
September 15, 2021, under the symbol “KTTA.”
Pasithea Clinics has clinic partnerships both in
the United States and in the United Kingdom to provide IV ketamine
treatment. In the U.K., it has partnered with ZEN Healthcare – a
network of health clinics in London. In the U.S., it has partnered
with The IV Doc, Inc., to provide in-home IV ketamine infusions.
Both partnerships offer rapid exposure and expansion
opportunities.
“With mental health cases on the rise, fueled
even more so by the pandemic, new treatment therapies are urgently
needed for those patients who are not responding to traditional
treatments. Evidence from dozens of trials over the past two
decades consistently supports the efficacy of ketamine in improving
symptoms in some mental health disorders. We are thrilled to be
able to provide this new treatment approach in the U.K. for those
patients who are deemed eligible to receive it,” stated Dr. Tiago
Reis Marques, CEO of Pasithea Therapeutics.
“This launch marks a significant milestone for
Pasithea Clinics and for patients in the U.K. suffering with mental
health conditions. We look forward to growing our specialty clinics
network while we simultaneously progress with our drug development
program to move the needle forward for better mental health care,”
concluded Dr. Reis Marques.
“This is an exciting opportunity for Pasithea
Clinics to offer ground-breaking therapies to those who can really
benefit. Our highly trained professionals are taking an integrative
approach that combines the IV ketamine infusion therapy with
psychiatric support. Today, there is still much misunderstanding
about ketamine and its application in a psychiatric setting, but
the potentially rapid and potent antidepressant effects are
beginning to be recognized within the regulatory and scientific
communities. People struggling with their mental health ultimately
deserve to explore every avenue to recovery without social stigmas.
We believe we can become the best-in-class provider of IV ketamine
treatments,” said Dr. Yassine Bendiabdallah, Managing Director of
Pasithea Clinics in the UK.
Ketamine is a U.S. Food and Drug Administration
(“FDA”) approved drug introduced to the medical community as an
anesthetic more than 50 years ago. It has recently been repurposed
for the treatment of psychiatric disorders using significantly
lower doses than in anesthesia and is now gaining ground as a
promising treatment for mental health disorders. In certain
psychiatric conditions, such as treatment-resistant depression
(“TRD”) and post-traumatic stress disorder (“PTSD”), it has shown
remarkable efficacy and a rapid and sustained effect.
Major Depression is the leading cause of
long-term disability worldwide, according to the World Health
Organization, with existing treatments having limited success
rates, numerous side effects and onset of action delayed by several
weeks. Studies have shown that with IV ketamine treatment, up to
70% of those who receive this treatment can eventually show a
clinical response. While the number of treatments suggested is done
on a case-by-case basis, a typical treatment plan consists of up to
six infusions in the interval of two to three weeks.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
About ZEN Healthcare
ZEN Healthcare is a luxury pharmacy and health
clinic in London with three branches – Baker Street, Knightsbridge
and Holborn. The clinics comprise a multidisciplinary group of
Private GPs, anti-ageing doctors, pharmacists, nutritionists,
dermatologists and psychotherapists, as well as intravenous
infusions specialists. ZEN Healthcare has been running pioneering
IV therapies in London for six years.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2023 to Apr 2024